REXAHN PHARMACEUTICALS, INC.

Form 8-K June 16, 2010

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): June 16, 2010 (June 14, 2010)

Rexahn Pharmaceuticals, Inc.

(Exact Name of Issuer as Specified in Charter)

DELAWARE (State or Other Jurisdiction of Incorporation or Organization) 001-34079 (Commission File Number)

11-3516358

(I.R.S. Employer Identification Number)

15245 Shady Grove Road, Suite 455
Rockville, MD

20850

(Zip Code)

(Address of Principal Executive Offices)

(240) 268-5300

(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Written communications pursuant to Pulo 425 under the Securities Act

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Soliciting material pursuant to Rule 14a-12 under the Exchange Act Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act	U	written communications pursuant to Rule 425 under the Securities Act
	o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act	o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
	o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Edgar Filing: REXAHN PHARMACEUTICALS, INC. - Form 8-K

Item 5.07 Submission of Matters to a Vote of Security Holders.

Rexahn Pharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders on June 14, 2010. At the meeting, the Company's stockholders (i) elected each of the Board's nominees to serve as directors of the Company until the 2011 annual meeting of stockholders, or until their successors are duly elected and qualified, and (ii) ratified the selection of ParenteBeard LLC as the Company's independent registered public accounting firm for the 2010 fiscal year.

The final number of votes cast for, against or withheld, as well as the number of abstentions and broker non-votes, with respect to each matter is set forth below.

	For	Against	Withheld	Abstained	Broker Non-Votes
1. Election of Directors					
Chang H. Ahn	40,795,497	202,209	-	1,553,963	13,715,536
Charles Beever	40,571,965	211,962	-	1,767,742	13,715,536
Kwang Soo Cheong	40,589,136	194,509	-	1,768,024	13,715,536
Tae Heum Jeong	40,583,686	200,259	-	1,767,724	13,715,536
David McIntosh	40,602,340	181,587	-	1,767,742	13,715,536
2. Ratification of the selection of					
ParenteBeard LLC as the Company's					
independent registered public accounting firm					
for the 2010 fiscal year.	54,002,411	447,528	-	1,817,266	-

Edgar Filing: REXAHN PHARMACEUTICALS, INC. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Rexahn Pharmaceuticals, Inc.

Date: June 16, 2010 By: /s/ Tae Heum Jeong

Name: Tae Heum Jeong

Title: Chief Financial Officer